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Letter to the editorSevere metabolic acidosis and Fanconi syndrome during
stavudine and abacavir therapy in a resource-limited setting
r
1Dear Editor,
Lactate acidosis due to mitochondrial toxicity has been par-
ticularly associated with stavudine and didanosine, but has
also been reported in regimens with nucleoside/nucleotide
reverse transcriptase inhibitors (NRTIs), which are consid-
ered to have less mitochondrial toxicity.1,2 Lactate acidosis
presents with malaise, nausea, vomiting, fatigue, tachyp-
noea, liver involvement, and dysrythmia, and can be lethal.1
Obesity and female gender are considered risk factors.1,3
Tenofovir, NRTI, is associated with Fanconi syndrome, which
is characterized by metabolic acidosis, hypophosphatemia,
hypokalemia, proteinuria, glucosuria, polyuria and renal
failure.3 Cases of Fanconi syndrome associated with NRTIs
have been published.4 Mitochondrial toxicity may contribute
to nephrotoxicity.4 Concomitant lactate acidosis and Fan-
coni syndrome with NRTIs has been reported.3,5 The ﬁrst-line
antiretroviral regimen in Suriname contains zidovudine,
lamivudine, and nevirapine. Available replacement drugs are
stavudine, abacavir, didanosine, tenofovir, and efavirenz. Lac-
tate measurements are unavailable in our resource-limited
setting.
A compliant HIV-infected obese East-Indian woman (BMI
46.4 kg/m2) in her mid-thirties received a regimen consisting
of abacavir, stavudine and lamivudine after the development
of nevirapine hepatotoxicity and zidovudine-related anemia.
She came to the emergency room three months after the
start of this changed regimen with development of dyspnea,
weakness, constipation, and vomiting. She was dyspneic and
had a respiratory rate of 42 breaths/minute, blood pressure of
150/90mmHg, heart rate of 110 bpm, temperature of 36.5◦C
and oxygen saturation measured by pulse oximetry of 88%.
Venous blood analyses revealed a pH of 7.21, base excess of
-14.3 mmol/L, bicarbonate value of 13.3 mmol/L, hypokalemia
(2.5 mmol/L; normal range 3.6-5.0), hypophosphataemia (0.50
mmol/L; normal range 1.00-1.60), and elevated LDH (1,031 IU/L;
normal range 240-480). She had proteinuria. Previous values
were normal. Her CD4 count was 175 cells/L (initial count
110 cells/L). Chest X-rays were normal. Ultrasonographic
abdominal examination revealedpossible abnormalities of the
2kidney parenchyma and hepatic steatosis. Initial intensive
care unit (ICU) admittance was not possible due to limited
capacity. Antiretroviral therapywas stopped, and she received
bicarbonate intravenously, vitamin B supplementation, sup-
portive ﬂuids, and oxygen. Metabolic acidosis persisted, with
arterial pH values reaching 7.2. Furthermore, she had polyuria,
with a mean urine output of 6.1 L/day. Despite ICU admission
on the 11th day, she died after 12 days of hospitalization.
The presence of severe metabolic acidosis and hepatic
steatosis in our case, despite discontinuation of antiretroviral
therapy, is suggestive of stavudine toxicity.1 A contribu-
tion of abacavir is possible. Lamivudine is less suspected.
Hypokalemia, hypophosphatemia, and polyuria, in our case,
are suggestive of Fanconi syndrome and should most likely be
ascribed to stavudine and possibly abacavir.3,4 We thus show
the development of severe metabolic acidosis and Fanconi
syndrome due to possible combined stavudine and abacavir
toxicity. An earlier case of stavudine-associated metabolic
acidosis in our setting had a better outcome. Eliminating
stavudine from ﬁrst-line regimens limits the possibility of
using ﬁxed-dose combinations in Suriname. These cases sup-
port the policy for resource-limited settings of using stavudine
as a last-resort treatment option. We emphasize that contin-
uous education is necessary despite limited resources.
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